/PRNewswire/ The "Osteoarthritis Therapeutics Market Analysis by Anatomy, by Drug Type, by Route of Administration, by Purchasing Pattern by Distribution.
A partnership with rival Merck & Co. to help make the shots, forged at the urging of the U.S. government, hasn’t lived up to expectations. The companies are now engaged in arbitration.
The growth of this market is driven by significant adoption of pain medications, increasing prevalence of osteoarthritis, growing population susceptible to osteoarthritis, and rising number of sports injuries. Knee osteoarthritis therapeutics is expected to hold the largest share of the osteoarthritis therapeutics market, by anatomy in 2020.
Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics. Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market. This can primarily be attributed to the high incidence of knee osteoarthritis. Viscosupplementation agents is expected to hold the largest share of the market, in 2020.
Based on drug type, the market is classified as, viscosupplementation agents, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids. The analgesics segment is subsegmented into duloxetine and acetaminophen, while the NSAIDs segment is subsegmente